A favorable metabolic and antiatherogenic profile in carriers of CYP21A2 gene mutations supports the theory of a survival advantage in this population

Hormone Research

Volumn 72, Issue 6, 2009, Pages 337-343

  Livadas, Sarantis ^a   Dracopoulou, Maria ^a   Lazaropoulou, Christina ^b   Papassotiriou, Ioannis ^b   Sertedaki, Amalia ^a   Angelopoulos, G Nick ^a   Chrousos, George P ^a   Dacou Voutetakis, Catherine ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b AGHIA SOPHIA CHILDREN S HOSPITAL   (Greece)

Author keywords

CYP21; CYP21A2; Insulin resistance; Metabolic syndrome, adrenarche; Metabolic syndrome, pubarche; Polycystic ovary syndrome; Premature adrenarche

Indexed keywords

GONADORELIN; GONADORELIN DERIVATIVE; PLASMINOGEN ACTIVATOR; STEROID 21 MONOOXYGENASE; TISSUE PLASMINOGEN ACTIVATOR;

ADOLESCENT; ARTICLE; ATHEROGENESIS; BODY MASS; CELL FUNCTION; CHEMICAL ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DEVELOPMENTAL STAGE; ENDOTHELIAL DYSFUNCTION; FEMALE; GENE MUTATION; GENETIC RISK; HETEROZYGOTE; HOMEOSTASIS; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INSULIN RELEASE; INSULIN RESISTANCE; MENARCHE; METABOLIC SYNDROME X; METHODOLOGY; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; PRECOCIOUS PUBERTY; PRIORITY JOURNAL; PROVOCATION TEST; PUBERTY; RISK FACTOR; SURVIVAL; THEORY; WAIST HIP RATIO;

ADOLESCENT; ATHEROSCLEROSIS; CASE-CONTROL STUDIES; CHILD; ENDOTHELIN-1; FEMALE; GLUCOSE TOLERANCE TEST; HETEROZYGOTE; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; INSULIN; INSULIN RESISTANCE; METABOLIC SYNDROME X; MUTATION; PITUITARY-ADRENAL SYSTEM; PLASMINOGEN ACTIVATOR INHIBITOR 1; RISK FACTORS; STEROID 21-HYDROXYLASE; TRIPTORELIN;

EID: 70350064011     PISSN: 03010163     EISSN: None     Source Type: Journal    
DOI: 10.1159/000249161     Document Type: Article

References (35)

1. New MI: Steroid 21-hydroxylase deficiency (congenital adrenal hyperplasia). Am J Med 1995; 16: 2S-8S.
2. Dacou-Voutetakis C, Dracopoulou M: Nonclassical congenital adrenal hyperplasia. Pediatr Endocrinol Rev 2006; 3(suppl 1):195-197.
3. White PC, Speiser PW: Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Endocr Rev 2000; 21: 245-291.
4. Hochberg Z, Etzioni A: Genetic selection in nonclassical adrenal hyperplasia. J Clin Endocrinol Metab 1995; 80: 325-326.
5. Witchel SF, Lee PA, Suda-Hartman M, Trucco M, Hoffman EP: Evidence for a heterozygote advantage in congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab 1997; 82:2097-2101.
6. Dacou-Voutetakis C, Dracopoulou M: High incidence of molecular defects of the CYP21 gene in patients with premature adrenarche. J Clin Endocrinol Metab 1999; 84: 1570-1574.
7. Chrousos GP: The role of stress and the hypothalamic- pituitary-adrenal axis in the pathogenesis of the metabolic syndrome: neuro-endocrine and target tissue-related causes. Int J Obes Relat Metab Disord 2000; 24:S50-S55.
8. Chiotis D, Krikos X, Tsiftsis G, Hatzisymeon M, Dacou-Voutetakis C: Body mass index and prevalence of obesity in subjects of Hellenic origin aged 0-18 years, living in the Athens area. Ann Clin Pediatr Univ Athen 2004; 51: 139-154.
9. Tanner JM, Whitehouse RH: Clinical longitudinal standards for height, weight, height velocity, weight velocity, and stages of puberty. Arch Dis Child 1976; 51: 170-179.
10. Ferriman D, Gallwey JD: Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961; 21: 1440-1447.
11. American Diabetes Association: Diagnosis and classification of diabetes mellitus. Diabetes Care 1997; 30:S42-S47.
12. Ahren B, Pacini G: Importance of quantifying insulin secretion in relation to insulin sensitivity to accurately assess beta cell function in clinical studies. Eur J Endocrinol 2004; 150: 97-104.
13. Ferrannini E, Gastaldelli A, Miyazaki Y, Matsuda M, Mari A, DeFronzo RA: Cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis. J Clin Endocrinol Metab 2005; 90: 493-500.
14. Wedell A, Luthman H: Steroid 21-hydroxylase deficiency: two additional mutations in salt-wasting disease and rapid screening of disease-causing mutations. Hum Mol Genet 1993; 2: 499-504.
15. Wilson R, Wei J-Q, Cheng K, Mercado A, New MI: Rapid deoxyribonucleic acid analysis by allele specific polymerase chain reaction for detection of mutations in the steroid 21-hydroxylase gene. J Clin Endocrinol Metab 1995; 80: 1635-1640.
16. Jensen CC, Cnop M, Hull RL, Fujimoto WY, Kahn SE: Cell function is a major contributor to oral glucose tolerance in high-risk relatives of four ethnic groups in the US. Diabetes 2002; 51:2170-2178.
17. Chandler WL, Trimble SL, Loo SC, Mornin D: Effect of PAI-1 levels on the molar concentrations of active tissue plasminogen activator (t-PA) and t-PA/PAI-1 complex in plasma. Blood 1990; 76: 930-937.
18. Mertens I, Verrijken A, Michiels JJ, Van der PM, Ruige JB, Van Gaal LF: Among inflammation and coagulation markers, PAI-1 is a true component of the metabolic syndrome. Int J Obes (Lond) 2006; 30: 1308-1314.
19. Diamanti-Kandarakis E, Palioniko G, Alexandraki K, Bergiele A, Koutsouba T, Bartzis M: The prevalence of 4G5G polymorphism of plasminogen activator inhibitor-1 (PAI-1) gene in polycystic ovarian syndrome and its association with plasma PAI-1 levels. Eur J Endocrinol 2004; 150: 793-798.
20. Andiran N, Yordam N, Kirazli S: Global fibrinolytic capacity is decreased in girls with premature adrenarche: a new pathological finding? J Pediatr Endocrinol Metab 2005; 18: 1373-1381.
21. Ibanez L, Aulesa C, Potau N, Ong K, Dunger DB, De Zegher F: Plasminogen activator inhibitor- 1 in girls with precocious pubarche: a premenarcheal marker for polycystic ovary syndrome? Pediatr Res 2002; 51: 244-248.
22. Silveira A: Postprandial triglycerides and blood coagulation. Exp Clin Endocrinol Diabetes 2001; 109:S527-S532.
23. Yuan J, Jia R, Bao Y: Aldosterone up-regulates production of plasminogen activator inhibitor-1 by renal mesangial cells. J Biochem Mol Biol 2007; 31: 180-188.
24. Pandey M, Loskutoff DJ, Samad F: Molecular mechanisms of tumor necrosis factor-mediated plasminogen activator inhibitor-1 expression in adipocytes. FASEB J 2005; 19: 1317-1319.
25. Rega G, Kaun C, Weiss TW, Demyanets S, Zorn G, Kastl SP, Steiner S, Seidinger D, Kopp CW, Frey M, Roehle R, Maurer G, Huber K, Wojta J: Inflammatory cytokines interleukin- and oncostatin M induce plasminogen activator inhibitor-1 in human adipose tissue. Circulation 2005; 111: 1938-1945.
26. Vulin AI, Stanley FM: Oxidative stress activates the plasminogen activator inhibitor type 1 (PAI-1) promoter through an AP-1 response element and cooperates with insulin for additive effects on PAI-1 transcription. J Biochem Chem 2004; 279: 25172-25178.
27. Morange PE, Aubert J, Peiretti F, Lijnen HR, Vague P, Verdier M, Négrel R, Juhan-Vague I, Alessi MC: Glucocorticoids and insulin promote plasminogen activator inhibitor 1 production by human adipose tissue. Diabetes 1999; 48: 890-895.
28. Charmandari E, Merke DP, Negro PJ, Keil MF, Martinez PE, Haim A, Gold PW, Chrousos GP: Endocrinologic and psychologic evaluation of 21-hydroxylase deficiency carriers and matched normal subjects: evidence for physical and/or psychologic vulnerability to stress. J Clin Endocrinol Metab 2004; 89:2228-2236.
29. Alessi MC, Juhan-Vague I: PAI-1 and the metabolic syndrome: links, causes, and consequences. Arterioscler Thromb Vasc Biol 2006; 26:2200-2207.
30. Vaindirlis I, Peppa-Patrikiou M, Dracopoulou M, Manoli I, Voutetakis A, Dacou-Voutetakis C: 'White coat hypertension' in adolescents: increased values of urinary cortisol and endothelin. J Pediatr 2000; 136:359-364.
31. Böhm F, Pernow J: The importance of endothelin- 1 for vascular dysfunction in cardiovascular disease. Cardiovasc Res 2007; 76: 8-18.
32. Schiffrin EL: Role of endothelin-1 in hypertension and vascular disease. Am J Hypertens 2001; 14:83S-89S.
33. Boesen EI, Pollock DM: Effect of chronic IL-infusion on acute pressor responses to vasoconstrictors in mice. Am J Physiol Heart Circ Physiol 2007; 293:H1745-H1749.
34. D'Orléans-Juste P, Plante M, Honoré JC, Carrier E, Labonté J: Synthesis and degradation of endothelin-1. Can J Physiol Pharmacol 2003; 81: 503-510.
35. Potau N, Rique S, Eduardo I, Marcos V, Ibanez L: Molecular defects of the CYP21 gene in Spanish girls with isolated precocious pubarche. Eur J Endocrinol 2002; 147: 485-488.